Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

ZenaTech anuncia el nuevo dron ZenaDrone IQ Quad para apoyar el crecimiento en los mercados de topografía, construcción, planificación urbana y obras públicas

View original at globenewswire.com
ZenaTech anuncia el nuevo dron ZenaDrone IQ Quad para apoyar el crecimiento en los mercados de topografía, construcción, planificación urbana y obras públicas VANCOUVER, Columbia Británica, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Industry analysts project that the global drone surveying market will grow more than 19% annually; from $2 billion today, the market could exceed $11 billion by 2033

    80% confidence
  • Land surveying is a large, growing and underserved market where speed, precision and repeatability are critical, and the IQ Quad was designed by ZenaDrone from scratch to meet exactly those requirements

    80% confidence
  • This launch represents a significant advance in our strategy to offer autonomous AI solutions designed specifically for high-value, data-intensive industries

    80% confidence
  • We believe the IQ Quad will significantly improve the productivity of our surveying professionals while strengthening our vertically integrated Drone-as-a-Service platform and significantly expanding recurring revenue opportunities

    80% confidence
  • Other analysts project that the broader surveying, geospatial and mapping services market could reach $50 billion in the next ten years as drone-enriched services and advanced data analytics progressively displace traditional methods and workflows

    80% confidence

Data points we hold from this source

ZenaTech, Inc. · daas locations us19 locations
ZenaTech, Inc. · daas locations international3 locations
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com